- $143.50bn
- $192.37bn
- $63.63bn
- 98
- 86
- 87
- 100
Pfizer Inc Pfizer Discontinues Phase 3 Trial of Sutent® in Metastatic Color
AnnouncementPfizer Inc - Statement re (Exubera Trial)
AnnouncementPfizer Inc - Pfizer, PlaNet Finance Partner to Study Options for Expanding Acces
AnnouncementPfizer Inc Pfizers Sutent is Recommended for Reimbursement for Gastrointestinal
AnnouncementPfizer Inc - Research Update
AnnouncementPfizer Inc - Regulatory Approval
AnnouncementPfizer Inc - Katrina relief
AnnouncementPfizer Inc Greg Simon, Noted Leader In Health And Science Policy, Joins Pfizer
AnnouncementPfizer Inc - Research Update
AnnouncementOffice of Fair Trade Merger Update
AnnouncementPfizer Inc - Exubera
AnnouncementPfizer Inc FDA Approves Intravenous Formulation Of Pfizers Revatio® (Silde
AnnouncementPfizer Inc - Pfizer and the European Foundation for the Study of Diabetes Announ
AnnouncementPfizer Inc - Research Update
AnnouncementPfizer Inc - Regulatory Approval
AnnouncementPfizer Inc - Statement re Shedlarz Cowen webcast invite
AnnouncementPfizer Inc - Pfizer Wins Key New York State Court Ruling on Celebrex
AnnouncementPfizer Inc - Pfizer Invites Public to View and Listen to Webcast of January 23 C
AnnouncementPfizer Inc - Pfizer and Express Scripts Sign Agreement
Announcement